Cell engineering

Ginkgo Bioworks and WARF Announce Partnership to Discover Next Generation GD2 CAR T-Cell Therapies

Retrieved on: 
Thursday, April 13, 2023
Neuroblastoma, DNA, CRISPR, Partnership, University, Therapy, Engineering, Wisconsin Alumni Research Foundation, Clinical trial, Bone marrow, Immunotherapy, ICD, Research, University of Wisconsin–Madison, CAR, Journal, Ginkgo, GD2, Cell engineering, Health, FDA, NYSE, WARF, Pharmaceutical industry, Vaccine, Cancer

MADISON, Wis. and BOSTON, April 13, 2023 /PRNewswire/ -- The Wisconsin Alumni Research Foundation (WARF), which has a mission of supporting research at the University of Wisconsin-Madison, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to leverage Ginkgo's proprietary high-throughput combinatorial CAR discovery and screening platform with the aim of discovering next generation GD2 CAR T-cell therapies with improved persistence, proliferation, fitness, and other functional properties to improve efficacy for the treatment of solid tumors.

Key Points: 
  • Through this partnership, Ginkgo will collaborate with the University of Wisconsin-Madison researchers Professor Krishanu Saha, Ph.D., as principal investigator (PI) and Dr. Christian Capitini, M.D.
  • Under this collaboration, Ginkgo will use its pooled CAR screening platform to design and characterize novel intracellular signaling domains that prevent the exhaustion of T-cells in the GD2 solid tumor context.
  • In addition, Ginkgo and WARF plan to collaborate on the development of a pooled in vivo screening platform to advance novel CAR discovery further.
  • WARF and Ginkgo hope to work towards solving this challenge by utilizing Ginkgo's high-throughput combinatorial CAR discovery platform.

Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on: 
Thursday, April 13, 2023
Research, Hospitals, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Memorial Sloan Kettering Cancer Center, KRAS, AACR, Associate, Synthetic biology, Lung, TCR, American Association for Cancer Research, Cell engineering, Patient, Cancer, Cell, MSK, Therapy, Peptide, Vaccine, Birth control

“Similar to our previously reported KRAS G12V data, our new preclinical data show a promising activity and tolerability profile in targeting KRAS G12D mutation that supports our mission to eradicate difficult to treat solid tumors with precision immunotherapies.

Key Points: 
  • “Similar to our previously reported KRAS G12V data, our new preclinical data show a promising activity and tolerability profile in targeting KRAS G12D mutation that supports our mission to eradicate difficult to treat solid tumors with precision immunotherapies.
  • The in vitro and in vivo preclinical data demonstrate a promising activity and tolerability profile of the KRAS G12D mutant TCR-engineered CD4+ and CD8+ T cell therapy.
  • The study supports the planned clinical development of this novel KRAS G12D mutant TCR-engineered CD4+ and CD8+ T cell therapy for treating patients with KRAS G12D mutant / HLA-A*11:01 cancers.
  • “I am hopeful that in future years we will see further advances resulting from our research lead to new mutation-specific TCR immunotherapies for patients with cancers that currently lack curative treatments.”

Affini-T Therapeutics Announces Licensing Agreement with Memorial Sloan Kettering Cancer Center to Expand Company’s Pipeline of Oncogenic Driver Programs

Retrieved on: 
Thursday, April 13, 2023
Biotechnology, Genetics, Health, Oncology, Damon Runyon Cancer Research Foundation, ASCI, KRAS, American Society for Clinical Investigation, Partnership, Senior, Research, Cancer, NIH, Axicabtagene ciloleucel, National Institutes of Health, Associate, Bangladesh Technical Education Board, National Cancer Institute, Science, National Institutes of Health MERIT Award, Cell engineering, MD, Patient, Engineering, Cell, MSK, Fred Hutchinson Cancer Research Center, Therapy, NCI, Society, Pharmaceutical industry, Klebanoff–Saric Wind Tunnel

Affini-T Therapeutics, Inc ., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced a licensing agreement with MSK.

Key Points: 
  • Affini-T Therapeutics, Inc ., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced a licensing agreement with MSK.
  • “We are committed to pushing forward a first-in-class pipeline of treatments targeting oncogene driver mutations for patients with solid tumor malignancies,” said Jak Knowles, M.D., Co-founder, President and Chief Executive Officer, Affini-T Therapeutics.
  • Dr. Klebanoff has contributed to the successful early phase development of numerous T cell-based therapies, notably Yescarta® (axicabtagene ciloleucel) at NCI.
  • “As a practicing medical oncologist, my singular professional focus and that of my lab is to address the urgent needs of patients with cancer.

Outpace Bio, a Leader in Protein Design & Cell Engineering, Adds Bahija Jallal to Board of Directors

Retrieved on: 
Thursday, March 23, 2023
Partnership, University, Health care, National Science Foundation, Hershenson, MedImmune, Cancer, General partnership, Playground Global, Microsoft, Bristol Myers Squibb, Research, Civilization, AstraZeneca, TCR, Penn State Board of Trustees, Woman of the Year, Jallal, Johns Hopkins University, Iran National Science Foundation, Patient, Trustee, Series, Apple, Biology, Cell engineering, Safety, Pharmaceutical industry, Vaccine, Science, Woman

Seattle, WA, March 23, 2023 (GLOBE NEWSWIRE) -- Outpace Bio , a company using protein design and cell engineering to create advanced cell therapies, today announced that Dr. Bahija Jallal has joined its Board of Directors.

Key Points: 
  • Seattle, WA, March 23, 2023 (GLOBE NEWSWIRE) -- Outpace Bio , a company using protein design and cell engineering to create advanced cell therapies, today announced that Dr. Bahija Jallal has joined its Board of Directors.
  • Bahija Jallal, CEO and Director of the Board of Immunocore, a commercial-stage biotechnology company oversaw the historic regulatory approval of the world’s first T cell receptor (TCR) therapy for a solid tumor.
  • “The Outpace team has potentially cracked the code by creating entirely new protein functions from scratch,” said Jallal.
  • The Series A funding has enabled Outpace to establish its cell programming platform and its partnership approach to development.

Cell Culture Protein Surface Coatings Global Market Report 2023: Growing Interest of Scientists and Biotechnology Companies in Stem Cell Research Boosts Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 22, 2023
Health, Biotechnology, CVD, Insulin, T cell deficiency, Corning Inc., Prevalence, Diabetes, 3D, Cancer, Molecular Devices, Research, Cell, Gelatin, USD, DSM-IV codes, 2D, Government, Incidence, Animal, Drug discovery, Growth, Cell engineering, Region, A-DNA, Cell adhesion, Protein Source of the Future...Now!, Vaccine, Dietary supplement, Fine chemical

The "Cell Culture Protein Surface Coatings Market by Coating (Self-coating, Pre-coating), by Protein Source, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Culture Protein Surface Coatings Market by Coating (Self-coating, Pre-coating), by Protein Source, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.
  • Increasing advancements in the research and development field, growing interest of scientists and biotechnology companies in stem cell research, rising demand of cell culture protein surface coating provides improved development and cell adhesion in in-vitro cell culture are some of the factors contributing to the market growth.
  • However, prohibitions against the use of protein coating materials derived from animals and the high cost of cell culture protein surface coatings products is expected to hinder the growth.
  • In 2022, North America region accounted for the highest revenue in the cell culture protein surface coatings market during the forecast period.

RoosterBio and Repligen Collaborate to Advance Scalable Exosome Bioprocessing

Retrieved on: 
Monday, March 13, 2023
Repligen Corporation Award in Chemistry of Biological Processes, CGMP, Exosome, Health, Gene, Cell engineering, Repligen, Chromatography, TFF, Pharmaceutical industry, Fine chemical

FREDERICK, Md., March 13, 2023 /PRNewswire-PRWeb/ -- RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, development services, cell engineering, and advanced therapy bioprocess solutions, today announced that it has selected Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, as a collaboration partner to advance scalable exosome bioprocessing.

Key Points: 
  • FREDERICK, Md., March 13, 2023 /PRNewswire-PRWeb/ -- RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, development services, cell engineering, and advanced therapy bioprocess solutions, today announced that it has selected Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, as a collaboration partner to advance scalable exosome bioprocessing.
  • RoosterBio's goal, in collaboration with Repligen, is to deliver solutions for manufacturing of exosomes using scalable and low shear technologies that enable cost-effective commercialization of these advanced therapies.
  • Repligen also brings to the collaboration the ability to develop exosome affinity resins for product purification.
  • We believe that this joint collaborative effort will provide commercially and clinically viable scalable solutions for exosome manufacturing," said Vikas Gupta, VP & GM, Downstream Bioprocessing and Gene Therapy of Repligen.

MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology

Retrieved on: 
Wednesday, March 8, 2023
Immunotherapy, Stanford University, Literature, Bone marrow, Therapy, Laboratory, University of Pennsylvania, Oncology, SAB, BS, Memorial Sloan Kettering Cancer Center, Internal medicine, Patient, Pharmacology, Translation, MUC1, Fordham University, United States Air Force Scientific Advisory Board, MD, ETH Zurich, Massachusetts Institute of Technology, Harvard Medical School, Cell, History of the University of Maryland, College Park, University, Biosensor, Harvard University, Doctor of Philosophy, Glycosylation, Chromatin, NF-κB, LSE, Research, Hematology, CAR, Cell engineering, UMBC, Aptamer, Management, Vaccine, Biology, Genetics, Medicine, Chemistry, Biochemistry

“With the formation of our Scientific Advisory Board, we are expanding the depth and breadth of our leadership team and scientific expertise with the next generation of leaders in the field of gene and cell therapy,” said Doug Doerfler, President and CEO of MaxCyte.

Key Points: 
  • “With the formation of our Scientific Advisory Board, we are expanding the depth and breadth of our leadership team and scientific expertise with the next generation of leaders in the field of gene and cell therapy,” said Doug Doerfler, President and CEO of MaxCyte.
  • Supported by deep technical knowledge, the SAB will help us unlock the power of cells, which will enhance our R&D activities and portfolio,” said Cenk Sumen, PhD, Chief Scientific Officer of MaxCyte.
  • Dr. Maus holds graduate degrees (M.D., Ph.D.) from University of Pennsylvania, where she completed graduate training with Dr. Carl June.
  • Her thesis exploited aptamers to overcome the conventional bottlenecks of electronic biosensing of small molecules in complex biological environments.

KORE Power Adds Dr. Liang Tao to its Leadership Team

Retrieved on: 
Tuesday, March 7, 2023
Automotive, Vehicle Technology, Technology, Engineering, Chemicals, Plastics, Sustainability, Manufacturing, Mobile, Wireless, Environment, Other Energy, Other Transport, Utilities, Batteries, Green Technology, Other Automotive, Alternative Energy, Energy, Transport, EV, Electric Vehicles, Alternative Vehicles, Fuels, Tao, Vehicle registration plates of Nepal, Principal, MBA, History of the University of Maryland, College Park, Albemarle Corporation, Cell, Data science, IP, Lawrence Berkeley National Laboratory, Mining, Tulane University, Multimedia, Private sector, University, Cell engineering, KORE, Albemarle, Electric battery, Management

KORE Power, Inc. (KORE), the leading U.S.-based developer of lithium-ion battery cells and manufacturer of integrated solutions for the e-mobility and energy storage systems has added Dr. Liang Tao, formerly of Rivian Automotive, Inc., to its leadership team.

Key Points: 
  • KORE Power, Inc. (KORE), the leading U.S.-based developer of lithium-ion battery cells and manufacturer of integrated solutions for the e-mobility and energy storage systems has added Dr. Liang Tao, formerly of Rivian Automotive, Inc., to its leadership team.
  • “Few people understand the battery market as thoroughly as Dr. Tao,” said KORE CEO and Co-founder Lindsay Gorrill.
  • Dr. Tao’s latest work was at Rivian, where he was the Principal of Battery Strategy and Cell Engineering.
  • “KORE Power is uniquely positioned as a domestic manufacturer with U.S.-owned IP to create mission-critical batteries to electrify the transportation sector and create a clean electric grid,” Dr. Tao said.

Kiromic BioPharma CEO Issues Letter to Stockholders

Retrieved on: 
Thursday, February 16, 2023
Stem Cells, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Research, Artificial Intelligence, Science, Clinical Trials, Toxicity, Stiris, Charles River Laboratories, MD Anderson Cancer Center, Mouse, Pharmacology, Investment, Cell engineering, Note, Safety, Patient, Clinical trial, Workforce, University, Senior, Letter, Special, Labcorp, Intelligence, Internet, FDA, Kiromal Katibin, Shareholder, IND, Medical imaging, Holding company, Pharmaceutical industry, Security (finance), Risk management

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, today issued the following letter to stockholders from its CEO Pietro Bersani.

Key Points: 
  • Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, today issued the following letter to stockholders from its CEO Pietro Bersani.
  • On behalf of my hardworking colleagues at Kiromic BioPharma and our dedicated Board of Directors, I’d like to thank our stockholders for their continued support as we prepare for an exciting future together.
  • Importantly, Kiromic will host a Special Meeting of Stockholders on March 7th, 2023.
  • On behalf of the Kiromic team as well as our Board of Directors, I want to thank our stockholders for their continued support.

Kevin D’Amour, PhD, Joins Stemson Therapeutics as Chief Scientific Officer

Retrieved on: 
Wednesday, February 1, 2023
Biotechnology, Health, Stem Cells, University of California, San Diego, University, B cell, Cell engineering, Therapy, Multimedia, William Stemson, Cell, Vertex, Doctor of Philosophy, De novo, Pharmaceutical industry, Biology

Stemson Therapeutics , a private biotechnology company developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles, announced today that Kevin D’Amour, a veteran cell therapy development expert, has joined Stemson as Chief Scientific Officer.

Key Points: 
  • Stemson Therapeutics , a private biotechnology company developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles, announced today that Kevin D’Amour, a veteran cell therapy development expert, has joined Stemson as Chief Scientific Officer.
  • Kevin brings two decades of stem cell-derived cell therapy development experience to the Stemson team.
  • View the full release here: https://www.businesswire.com/news/home/20230201005196/en/
    “We are delighted to have Kevin join our team and bring his extensive experience in cell therapy development,” said Geoff Hamilton, Stemson’s Cofounder and Chief Executive Officer.
  • After his time at ViaCyte, Kevin was Chief Scientific Officer of Brooklyn ImmunoTherapeutics where he focused on developing cell therapies using mRNA-based cell engineering technology.